MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Quality of life and patient reported outcomes with subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 BeyoND study

    W. Poewe, F. Stocchi, L. Adar, T. Yardeni, A. Espay (Innsbruck, Austria)

    Objective: To review quality of life and other patient reported outcomes data from the ND0612 BeyoND study. Background: ND0612 is in development as a continuous,…
  • 2022 International Congress

    Impact of istradefylline on the adjustment of levodopa dose escalation in Parkinson’s disease: Results of the ISTRA ADJUST PD randomized, controlled study

    T. Hatano, O. Kano, R. Sengoku, N. Yanagisawa, H. Nagayama (Tokyo, Japan)

    Objective: To evaluate the effect of istradefylline (IST), an adenosine A2A receptor antagonist, on the adjustment of levodopa dose escalation in patients with Parkinson’s disease…
  • 2022 International Congress

    Computer vision can detect changes in bradykinesia associated with dopaminergic state in Parkinson’s disease

    JF. Martín-Rodríguez, S. Camba Fernandez, D. Rodriguez Gordo, S. Garcia-Ojeda, B. Benitez Zamora, L. Muñoz-Delgado, F. Carrillo, P. Mir (Sevilla, Spain)

    Objective: To evaluate the classification accuracy of a computer vision-based feature extraction and classifier method to detect changes in finger tap bradykinesia associated with dopaminergic…
  • 2022 International Congress

    A case with clinical features of alpha-synuclein- and tauopathy: Genetic and histopathological workup.

    D. Gruber, C. Mawrin, A. Vogel, T. Usnich, N. Brueggemann, C. Klein, P. Bauer, F. Gandor, G. Ebersbach (Beelitz-Heilstaetten, Germany)

    Objective: Here, we present a clinical case that mimicked the coincidence of idiopathic Parkinson’s disease (PD) and tauopathy. Background: Mutation in leucine-rich-repeat-kinase 2 (LRRK2) gene…
  • 2022 International Congress

    Multimodal mechanistic disease stratification in sporadic Parkinson’s disease

    T. Payne, T. Burgess, M. Sassani, S. Roscoe, S. Bradley, A. Anton, E. Reed, I. Wilkinson, H. Mortiboys, T. Jenkins, O. Bandmann (Sheffield, United Kingdom)

    Objective: To mechanistically stratify Parkinson’s disease (PD), applying a combination of putaminal 31Phosphorus magnetic resonance spectroscopy (31P-MRS) with detailed assessment of mitochondrial and lysosomal function…
  • 2022 International Congress

    Concomitant Medication Use and Levodopa Equivalent Daily Dose Requirements After Foslevodopa/foscarbidopa Initiation

    D. Santos Garcia, L. Bergmann, B. Bergmans, F. Bergquist, S. Criswell, V. Fung, J. Jia, P. Kukreja, N. Pavasia, W. Robieson, Z. Zhang, D. Standaert (A Coruña, Spain)

    Objective: To evaluate patterns of concomitant medication use and levodopa equivalent daily dose (LEDD) during a 52 week study with foslevodopa/foscarbidopa (LDP/CDP). Background: LDP/CDP is…
  • 2022 International Congress

    White matter microstructural differences between essential tremor and Parkinson’s disease evaluated using advanced MRI biomarkers

    M. Bergamino, S. Aslam, J. Knittel, M. Olson, A. Stokes (Phoenix, USA)

    Objective: To study white matter differences between essential tremor (ET) and Parkinson’s disease (PD) using standard diffusion tensor magnetic resonance imaging (DTI) and fixel-based analysis.…
  • 2022 International Congress

    Adrenergic blockers and statins are associated with later age of onset in Parkinson’s disease

    C. Malatt, I. Khatiwala, M. Rangwala, A. Maleki, E. Hogg, E. Tan, M. Tagliati (Los Angeles, USA)

    Objective: To evaluate the association of anti-hypertensives, non-steroidal anti-inflammatories (NSAIDs), statins, diabetes medications, smoking and family history of idiopathic Parkinson’s disease (iPD) with age of…
  • 2022 International Congress

    Characterization of neuromelanin MRI as a potential Parkinson’s Disease biomarker in a multi-site longitudinal study

    M. Ingalhalikar, H. Pham, L. Bracoud, RM. Hutchison, K. Evans, T. Dam, M. Sampat, J. Schaerer, C. Conklin, J. Suhy, D. Scott (San Mateo, USA)

    Objective: To investigate (1)longitudinal change and (2)cross-sectional vendor differences in neuromelanin MRI in substantia nigra pars compacta(SNpc) in PD patients. Background: Neuromelanin(NM) MRI is a…
  • 2022 International Congress

    Dopaminergic modulation of express reaching responses in Parkinson’s disease

    M. Gilchrist, R. Kozak, B. Corneil, P. Macdonald (London, Canada)

    Objective: This study investigates the role of dopamine (DA) in modulation of automatic stimulus-driven responses. We investigated the effect of PD, DA medication, and instruction…
  • « Previous Page
  • 1
  • …
  • 340
  • 341
  • 342
  • 343
  • 344
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley